To evaluate the ability of galunisertib to inhibit TGFβ1-mediated EMT, a TGFβ-dependent model system was employed using the mouse pancreatic cancer cell line KPC-M09. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.